A new vaccine is on the horizon for maternal immunization to protect newborns from pertussis. An early-stage clinical trial was recently completed in 179 women and infants to test safety, but not efficacy of the maternal immunization vaccine development hong kong. This research is being conducted by Eli Lilly and Company (a pharmaceutical company) in partnership with ACADIA Pharmaceuticals, Inc., a biotechnology company that specializes in a class of drugs called JAK inhibitors.
Results
The study showed that the vaccine was safe to use during pregnancy, but did not show any efficacy against immunity after birth given past pertussis vaccines have been shown effective at this point as well as when administered postpartum.
Planned Trials
Research has also been conducted to develop a second-generation pertussis vaccine which is being tested with an additional booster dose in adults. Also, a study to test the safety and efficacy of Acella™ pertussis antigen (which, like the vaccine, contains a killed whole-cell Bordetella pertussis [pertussis bacteria] component) in adults is underway.
Recommendations
Although unconfirmed efficacy against disease after birth was not shown by the current trial, research continues to develop improved bacterial infections vaccines therapies hong kong that can protect children from infection by both vaccines and disease after birth as well.
The American College of Obstetricians and Gynecologists (ACOG) has the following recommendations regarding pertussis vaccination:
ACOG guidelines state that pregnant patients should be advised about the benefits and risks of immunization, given appropriate information, and encouraged to obtain immunizations. ACOG also recommends that prenatal care providers review vaccination records, assess patient history to determine if any immunizations are needed based on individual risk factors, and administer age-appropriate vaccines according to ACIP recommendations. Pertussis vaccination is recommended for any woman who did not receive 3 doses of pertussis-containing vaccine during childhood in a primary series or booster dose as previously recommended by ACIP. Pertussis-containing vaccine is contraindicated in anyone with a known hypersensitivity to any component of the vaccine. ACOG guidelines do not recommend that a pregnant woman receive the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine during pregnancy because there is insufficient data as to whether this vaccination protects from pertussis disease.
Pertussis is most likely acquired by infants born to women who are not vaccinated with antepartum oral probenecid, chloramphenicol, or erythromycin.
Pertussis vaccination should be administered intramuscularly in infants and children at 2–6 months of age, and in older children at ages 10–13 years.
Children with pertussis who are up-to-date with their immunizations can be considered to be adequately protected and can use some of the same precautions as adults.
After a child is vaccinated, he or she should receive a Tdap booster Vaccination within 4 weeks after the last dose of Tdap is recommended for all persons who have not been fully vaccinated. Immunized persons should receive one further dose regardless of the time since their previous tetanus toxoid-containing vaccine or diphtheria toxoid-containing vaccine.
